NCT06213428

Brief Summary

Modulation of our gut microbiota through probiotics, can improve our emotional state, decrease pain sensitivity, improve cognitive processes, increase neurotransmitter levels and alter functional connectivity. In addition, probiotics regulate estrogen levels. Estrogen levels have been recognized to influence the gut microbiota, impact neural activity, memory, and cognition. This study aims 1) to determine whether probiotics can increase the propensity for synaptic plasticity in females and 2) to determine if there are differences in the propensity for plasticity depending on the phase of the menstrual cycle.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Jan 2024

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 26, 2023

Completed
6 days until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

January 19, 2024

Status Verified

January 1, 2024

Enrollment Period

1.3 years

First QC Date

December 26, 2023

Last Update Submit

January 9, 2024

Conditions

Keywords

Probiotic

Outcome Measures

Primary Outcomes (1)

  • Change Motor Evoked Potentials (MEPs)

    Change in MEPs using TMS

    Immediately before intervention, immediately following 4 week intervention

Secondary Outcomes (1)

  • Short Interval intracortical inhibition (SICI)

    Immediately before intervention, immediately following 4 week intervention

Study Arms (2)

Active: Probiotic

ACTIVE COMPARATOR

Progressive Perfect Probiotic 120 Billion CFU containing the following strains will be used: Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium animalis subsp.lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium bifidum, Bifidobacterium longum subsp. Longum. Participants will be required to take one capsule a day, for 28 days.

Biological: Progressive Perfect Probiotic

Placebo Probiotic

PLACEBO COMPARATOR

A placebo that is identical in capsule size and colour to the active probiotic capsule will be used. This will ensure participants and experimenters are masked during each intervention period. Participants will be required to take one capsule a day for 28 days.

Other: Placebo

Interventions

Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.

Active: Probiotic
PlaceboOTHER

Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.

Placebo Probiotic

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • right handed, females between 18-35 years old with a regular menstrual cycle (approximately 26-30 days)

You may not qualify if:

  • contradictions to TMS
  • contradictions to probiotic
  • Females who use hormone altering devices (i.e. oral contraceptives)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McMaster Unviersity

Hamilton, Ontario, L8S 4K1, Canada

Location

Central Study Contacts

Aimee J Nelson, PhD

CONTACT

Faith C Adams, BSc

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
all investigators and participants will be masked to which condition they receive
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

December 26, 2023

First Posted

January 19, 2024

Study Start

January 1, 2024

Primary Completion

May 1, 2025

Study Completion

May 1, 2025

Last Updated

January 19, 2024

Record last verified: 2024-01

Locations